000			03624nam a22003855i 4500
001			309895
003			MX-SnUAN
005			20160429160329.0
007			cr nn 008mamaa
008			150903s2007 sz | o |||| 0|eng d
020			_a9783764377830 _99783764377830
024	7		_a10.1007/9783764377830 _2doi
035			_avtls000362834
039		9	_a201509030649 _bVLOAD _c201405070335 _dVLOAD _y201402211059 _zstaff
040			_aMX-SnUAN _bspa _cMX-SnUAN _erda
050		4	_aRM1-950
100	1		_aReeves, Jacqueline D. _eeditor. _9350390
245	1	0	_aEntry Inhibitors in HIV Therapy / _cedited by Jacqueline D. Reeves, Cynthia A. Derdeyn.
264		1	_aBasel : _bBirkhäuser Basel, _c2007.
300			_aIx, 200 páginas 18 ilustraciones _brecurso en línea.
336			_atexto _btxt _2rdacontent
337			_acomputadora _bc _2rdamedia
338			_arecurso en línea _bcr _2rdacarrier
347			_aarchivo de texto _bPDF _2rda
490	0		_aMilestones in Drug Therapy
500			_aSpringer eBooks
505	0		_ato entry inhibitors in the management of HIV infection -- The challenge of HIV sequence diversity in the envelope glycoprotein -- Attachment of human immunodeficiency virus to cells and its inhibition -- Inhibitors that target gp120-CD4 interactions -- Inhibitors that target gp120 interactions with coreceptor -- Inhibitors that target fusion -- HIV-1 entry inhibitors as microbicides -- Entry inhibition of HIV-1 subtype C isolates -- The utility of coreceptor typing in the clinic -- Future clinical prospects for entry inhibitors -- Enfuvirtide: from basic science to FDA approval -- Targets for drug development — past and present.
520			_aEntry Inhibitors in HIV Therapy presents the current status of this relatively new and highly dynamic class of inhibitors and provides a unique overview of obstacles and considerations for HIV entry inhibition compared to other antiretroviral targets. The introductory chapters of this book present an overview of entry inhibitors, review current knowledge of how Env mediates entry, and discuss the challenge of genetic diversity in this region of the viral genome. Subsequent chapters feature current information on individual classes of entry inhibitors that target each step of the virus entry pathway, from attachment to membrane fusion. There is an emphasis on the complex determinants of entry inhibitor susceptibility, resistance mechanisms, the need for clinical phenotyping, and how these issues create new challenges for antiretroviral therapy. Encouraging pre-clinical studies of entry inhibitors as microbicidesare also discussed. The final chapters highlight the current status of entry inhibitors in clinical studies, the major milestone achieved with FDA approval of enfuvirtide, and review drug development, past and present. In summary, this book presents a comprehensive and current overview of entry inhibitors from an expert panel of authors with diverse backgrounds and perspectives, incorporating many unrelenting successes against a backdrop of formidable challenges. It is of interest to basic science researchers as well as clinical physicians.
590			_aPara consulta fuera de la UANL se requiere clave de acceso remoto.
700	1		_aDerdeyn, Cynthia A. _eeditor. _9350391
710	2		_aSpringerLink (Servicio en línea) _9299170
776	0	8	_iEdición impresa: _z9783764377823
856	4	0	_uhttp://remoto.dgb.uanl.mx/login?url=http://dx.doi.org/10.1007/978-3-7643-7783-0 _zConectar a Springer E-Books (Para consulta externa se requiere previa autentificación en Biblioteca Digital UANL)
942			_c14
999			_c309895 _d309895